prikaz prve stranice dokumenta Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
  Preuzmi
PDF 1.06 MB
Znanstveni rad - Izvorni znanstveni rad
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
Inflammatory Bowel Diseases, 30 (2024), 5; 768-779. https://doi.org/10.1093/ibd/izad135
(TFB Study Group) Resál, Tamás; Bacsur, Péter; Keresztes, Csilla; Bálint, Anita; Bor, Renáta; Fábián, Anna; Farkas, Bernadett; Katsanos, Kostas; Michalopoylos, George; Ribaldone, Davide Giuseppe; Attauabi, Mohamed; Zhao, Mirabella; Barak, Hadar Amir; Yanai, Henit; Bezzio, Cristina; Rispo, Antonio; Castiglione, Fabiana; Bar-Gil Shitrit, Ariella; Pugliese, Daniela; Armuzzi, Alessandro; Savarino, Edoardo Vincenzo; Kolar, Martin; Lukáš, Milan; Chashkova, Elena; Filip, Rafał; Rozieres, Aurore; Nancey, Stéphane; Krznarić, Željko; Schäfer, Eszter; Szamosi, Tamás; Sarlós, Patrícia; Franko, Matej; Drobne, David; Knyazev, Oleg V; Kagramanova, Anna V; Limdi, Jimmy; Wetwittayakhlang, Panu; Lakatos, Peter L; Maharshak, Nitsan; Bannon, Lian; Nyári, Tibor; Szepes, Zoltán; Farkas, Klaudia; Molnár, Tamás Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Resál, T., Bacsur, P., Keresztes, C., Bálint, A., Bor, R., Fábián, A. ... Molnár, T. (2024). Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases, 30. (5), 768-779. doi: 10.1093/ibd/izad135

Resál, Tamás, et al. "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study." Inflammatory Bowel Diseases, vol. 30, br. 5, 2024, str. 768-779. https://doi.org/10.1093/ibd/izad135

Resál, Tamás, Péter Bacsur, Csilla Keresztes, Anita Bálint, Renáta Bor, Anna Fábián, Bernadett Farkas, et al. "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study." Inflammatory Bowel Diseases 30, br. 5 (2024): 768-779. https://doi.org/10.1093/ibd/izad135

Resál, T., et al. (2024) 'Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study', Inflammatory Bowel Diseases, 30(5), str. 768-779. doi: 10.1093/ibd/izad135

Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, i sur.. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases [Internet]. 01.05.2024. [pristupljeno 23.11.2024.];30(5):768-779. doi: 10.1093/ibd/izad135

T. Resál, et al., "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study", Inflammatory Bowel Diseases, vol. 30, br. 5, str. 768-779, Svibanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:675377. [Citirano: 23.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:675377
Podaci o radu
Naslov (engleski)Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
AutorTamás Resál
AutorPéter Bacsur
AutorCsilla Keresztes
AutorAnita Bálint
AutorRenáta Bor
AutorAnna Fábián
AutorBernadett Farkas
AutorKostas Katsanos
AutorGeorge Michalopoylos
AutorDavide Giuseppe Ribaldone
AutorMohamed Attauabi
AutorMirabella Zhao
AutorHadar Amir Barak
AutorHenit Yanai
AutorCristina Bezzio
AutorAntonio Rispo
AutorFabiana Castiglione
AutorAriella Bar-Gil Shitrit
AutorDaniela Pugliese
AutorAlessandro Armuzzi
AutorEdoardo Vincenzo Savarino
AutorMartin Kolar
AutorMilan Lukáš
AutorElena Chashkova
AutorRafał Filip
AutorAurore Rozieres
AutorStéphane Nancey
AutorŽeljko Krznarić
MBZ: 75865
AutorEszter Schäfer
AutorTamás Szamosi
AutorPatrícia Sarlós
AutorMatej Franko
AutorDavid Drobne
AutorOleg V Knyazev
AutorAnna V Kagramanova
AutorJimmy Limdi
AutorPanu Wetwittayakhlang
AutorPeter L Lakatos
AutorNitsan Maharshak
AutorLian Bannon
AutorTibor Nyári
AutorZoltán Szepes
AutorKlaudia Farkas
AutorTamás Molnár
KolaboracijaTFB Study Group
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background and aims: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC. Methods: This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed. Results: A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported. Conclusions: TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInflammatory Bowel Diseases
Brojčani podacivol. 30, br. 5, str. 768-779
p-ISSN1078-0998
e-ISSN1536-4844
DOIhttps://doi.org/10.1093/ibd/izad135
URN:NBNurn:nbn:hr:105:675377
Datum objave publikacije2024-05-01
URL dokumentahttps://academic.oup.com/ibdjournal/article/30/5/768/7237867
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2024-09-03 10:51:07